GB5121 in Adult Subjects With Relapsed/Refractory CNS Lymphoma
Status:
Not yet recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
A 3-part study, comprising a phase 1b dose escalation, dose expansion, and a phase 2, to
assess the safety, tolerability, dose-limiting toxicity(ies), maximum tolerated dose, and/or
optimal biological dose, determine the recommended phase 2 dose, preliminary anti-tumor
activity and efficacy of the recommended phase 2 dose of GB5121.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
GB005, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.